We previously reported that XPO1 inhibitors, including leptomycin B (LMB) and Selinexor, enhanced the replication of oncolytic myxoma virus (MYXV), a member of the leporipoxvirus genus of poxviridae, in diverse types of cultured human cancer cells where intrinsic cellular pathways restrict virus replication [26]. Here, XPO1 is linked to cancer.